About
About NextCure, Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Visit company website
5 years, 5 months ago
NextCure, Inc is currently in a long term downtrend where the price is trading 24.3% below its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.1.
NextCure, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 41.5% to $-15M since the same quarter in the previous year.
Finally, its free cash flow grew by 32.8% to $-7M since the same quarter in the previous year.
Based on the above factors, NextCure, Inc gets an overall score of 2/5.